The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) took place at the Georgia World Congress Center in Atlanta, USA, 3rd-6th March 2013.

Conference highlights

'Functional' cure in a child

HIV persists but no signs of new virus production after 12 months off treatment.

Conference bulletins

In English, French, Spanish, Portuguese, Italian and Russian.

HIV risk in US gay men

Black gay men run higher risk of HIV infection despite fewer partners.


TB treatment

Once-weekly continuation phase TB treatment equals standard of care.

Hepatitis C treatment

Real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection.

Condom use

First estimate since 1989 of condom efficacy in preventing transmission of HIV during anal sex.


Pre-exposure prophylaxis

The VOICE trial's disappointing result poses big questions for PrEP.

Tweets from CROI 2013

We used Storify to capture some of the tweets from the conference.

Cenicriviroc phase IIb study

Dual CCR5/CCR2 inhibitor has anti-inflammatory as well as anti-HIV effect.


aidsmap news from CROI 2013

← First12Next →

Editors' picks from other sources

Conference emails

Sign up for our conference email bulletins

Official conference website

Find out more about the conference and view the program on the official conference website.

Visit the official CROI website >

aidsmap news iPhone app

Keep up to date with the latest HIV news using the free aidsmap news iPhone app.

Download the app >

NAM is partnering with gTt (Barcelona), GAT (Lisbon) and LILA (Como) to deliver the CROI 2013 bulletins, which have also been made possible thanks to support from Bristol-Myers Squibb. NAM’s wider conference news reporting services have been supported by Abbott, Boehringer Ingelheim, Janssen, Roche and ViiV Healthcare. The funders have no editorial control over the content of the materials.